Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL16 GAVe vs GVe in untreated high-risk CLL
2023-506414-46-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, obinutuzumab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by University of Cologne. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
acalabrutinibobinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-506414-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506414-46-00.